Changchun GeneScience Pharmaceutical Co., Ltd.
PharmaChangchun, Jilin, China · Est. 1993
Changchun GeneScience Pharmaceutical Co., Ltd. is a Chinese biopharmaceutical company specializing in the development and manufacturing of recombinant human growth hormone and other biological drugs.
15
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
22
Indications↗
Distinct diseases across all programs
105
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
15 drugs in development
Phase 32
Phase 23
Phase 19
Preclinical3
By Therapeutic Area
top 3
Oncology
422%
Ophthalmology
211%
Musculoskeletal
16%
R&D Momentum
71/100
Pipeline Velocity
53/100
Trial Completion Rate
97/100
Pipeline Concentration
44/100
Pipeline Freshness
62/100
Strategic Signals
- ↗Active in Ophthalmology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Completed
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
Sep 18, 2026
Recruiting
A Multicenter, Randomized Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
Sep 17, 2026
Recruiting
A Study to Evaluate the Safety and Tolerability of Multiple Ascending Doses of GS3-007a Dry Suspension in Patients With PGHD and to Evaluate the Efficacy and Safety of 52-week of Treatment With GS3-007a Dry Suspension: a Two-part, Multicenter, Randomized, Phase Ib/II Clinical Trial
Earlier
Aug 28, 2026TrialA Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci164 in Healthy Adult Participants in China
Aug 7, 2026TrialA Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Jul 25, 2026TrialA Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.
Jul 9, 2026TrialPhase IV Clinical Study Evaluating Efficacy and Safety of Recombinant Human Growth Hormone Injection for Adult Short Bowel Syndrome
Jul 7, 2026TrialA Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial in Healthy Adult Participants in China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of GenSci144
3 more events
Jun 24, 2026TrialA Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
Apr 23, 2026TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants
Apr 20, 2026TrialGS1-144 in Participants With Hepatic Impairment and Healthy Female
Details
Company Info
Therapeutic Focus
Growth hormonePeptidesBiologics
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Oncology(4 drugs)
1
2
1
2
—
Oncology(4 drugs)
Ophthalmology(2 drugs)
—
1
1
—
—
Ophthalmology(2 drugs)
Unknown / Other(11 drugs)
1
7
2
1
—
Unknown / Other(11 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)